109 related articles for article (PubMed ID: 5200044)
1. [Personal experiences in the treatment of internal diseases with ornithine aspartate].
Perinović M; Robović Z; Grujić M; Ljubojević S
Med Arh; 1969; 23(3):29-32. PubMed ID: 5200044
[No Abstract] [Full Text] [Related]
2. [Experiences with ornithine-aspartate in liver diseases].
Aschke J
Med Welt; 1969 Mar; 12():657-62. PubMed ID: 5767441
[No Abstract] [Full Text] [Related]
3. [Further clinical experiences with ornithine aspartate in liver diseases].
Wotzka R; Weber D
Ther Ggw; 1972 Mar; 111(3):400-12. PubMed ID: 5024593
[No Abstract] [Full Text] [Related]
4. [Clinical experiences in liver diseases (specially in patients with fatty liver due to alcoholism and food poisoning) under monotherapy with ornithine aspartate].
Hunold W
Z Allgemeinmed; 1973 Apr; 49(10):469-72. PubMed ID: 4580434
[No Abstract] [Full Text] [Related]
5. [On the therapy of liver diseases with ornithine aspartate].
Melzer H; Weber D; Wotzka R
Med Klin; 1969; 64(35):1541-4. PubMed ID: 5354488
[No Abstract] [Full Text] [Related]
6. [Our clinical experience with ornithine aspartate].
Szirmai E
Minerva Med; 1971 Jun; 62(47):2376-82. PubMed ID: 5087700
[No Abstract] [Full Text] [Related]
7. [Influence of ornithine aspartate on the experimentally induced hyperammoniemia. Clinico-experimental study].
Henglein-Ottermann D
Ther Ggw; 1976 Sep; 115(9):1504-18. PubMed ID: 968783
[No Abstract] [Full Text] [Related]
8. [Protection of the liver and liver therapy with Hepamerz].
Heynen U
Z Allgemeinmed; 1970 Jan; 46(2):87-8. PubMed ID: 5439291
[No Abstract] [Full Text] [Related]
9. [Study of the treatment of liver damage due to several causes in tuberculosis, using ornithine-aspartate].
Seki S
Iryo; 1966 Apr; 20(4):354-63. PubMed ID: 5974194
[No Abstract] [Full Text] [Related]
10. [Clinical study on the effects of L-ornithine-L-aspartate on liver dysfunction].
Kosozu K
Iryo; 1966 Apr; 20(4):339-46. PubMed ID: 5974192
[No Abstract] [Full Text] [Related]
11. [Clinical experiences with heparmez].
Baumann M
Z Allgemeinmed; 1970 Jun; 46(17):895-900. PubMed ID: 5509064
[No Abstract] [Full Text] [Related]
12. Experimental liver damage in potassium depletion, inhibited by L-ornithine-L-aspartate.
Raab WP
Arzneimittelforschung; 1971 Oct; 21(10):1620-1. PubMed ID: 5171899
[No Abstract] [Full Text] [Related]
13. [Betaine aspartate in the therapy of liver diseases].
Cairella M; Volpari B
Clin Ter; 1972 Mar; 60(6):513-34. PubMed ID: 5038777
[No Abstract] [Full Text] [Related]
14. [Antilipidemic activity of ethyl-chloro-phenoxy-isobutyrate or clofibrate].
Barisone D; Gallo G; Accardo S
Minerva Med; 1969 Jan; 60(6):174-80. PubMed ID: 5776766
[No Abstract] [Full Text] [Related]
15. [Intravenous administration of ornithine aspartate to patients with hepatic diseases].
Schäfer W
Munch Med Wochenschr; 1968 Oct; 110(43):2521-5. PubMed ID: 5755238
[No Abstract] [Full Text] [Related]
16. [Personal experiences with coroverlan digoxin in the therapy of cardiac insufficiency].
Grujić M; Perinović M
Med Arh; 1969; 23(5):61-7. PubMed ID: 5201556
[No Abstract] [Full Text] [Related]
17. [On the use of K and Mg aspartate in the treatment of some cardiovascular diseases].
Gavrilescu S
Med Interna (Bucur); 1968 Mar; 20(3):301-7. PubMed ID: 5668976
[No Abstract] [Full Text] [Related]
18. [On a combination of amino acids and vitamins in the treatment of liver diseases].
Bazzicalupo G; Pietranera P
Minerva Med; 1967 Apr; 58(34 Suppl):1587-92. PubMed ID: 4226043
[No Abstract] [Full Text] [Related]
19. [Therapy with the sulfated polyanion SP 54].
Weyer H; Muth HW
Med Welt; 1973 May; 24(19):800-2. PubMed ID: 4269029
[No Abstract] [Full Text] [Related]
20. [Therapeutic activity of betaine aspartate].
Nicrosini F
Clin Ter; 1972 May; 61(3):227-36. PubMed ID: 5050945
[No Abstract] [Full Text] [Related]
[Next] [New Search]
